Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Verheij VA, Diecidue RJ, Botman E, Harrington JD, Haga N, Hidalgo-Bravo A, Delai PLR, Madhuri V, Al Mukaddam M, Zhang K, Cho TJ, Morhart R, Keen R, De Cunto CL, Friedman CS, Grunwald Z, Zasloff M, Netelenbos JC, Hsiao E, Kaplan FS, Pignolo RJ, Scott C, Eekhoff EMW. Palovarotene in fibrodysplasia ossificans progressiva: review and perspective. Expert Opin Pharmacother. 2025 Feb; 26(3):291-299.
-
Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient Rep Outcomes. 2024 Dec 19; 8(1):149.
-
Quintanilla ME, Morales P, Santapau D, Gallardo J, Rebolledo R, Riveras G, Acu?a T, Herrera-Marschitz M, Israel Y, Ezquer F. Morphine self-administration is inhibited by the antioxidant N-acetylcysteine and the anti-inflammatory ibudilast; an effect enhanced by their co-administration. PLoS One. 2024; 19(10):e0312828.
-
Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20; 42(36):4271-4281.
-
Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, Kamel H, Lewis BS, Cornel JH, Kowey PR, Horrow J, Strony J, Plotnikov AN, Li D, Weng S, Donahue J, Gibson CM, Steg PG, Mehran R, Weitz JI, Johnston SC, Hankey GJ, Harrington RA, Lam CSP. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 Nov; 277:145-158.
-
Burgei J, Alsheimer KM, Lantry J, Hehn B. Mediastinal lymphadenopathy due to VEXAS syndrome. BMJ Case Rep. 2024 Aug 08; 17(8).
-
George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024 08 01; 7(8):e2429783.
-
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Oncologist. 2024 Jul 05; 29(7):581-588.
-
Zheng R, Lam E, Altshuler P, Crutcher M, Lavu H, Yeo CJ, Stickle D, Leiby B, Kraft WK. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). Int J Clin Pharmacol Ther. 2024 Jul; 62(7):319-325.
-
Morgans AK, Grossman JP, Paracha N, Ladino D, Tyas E, Rodriguez-Santamaria F, Shore N. Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. J Manag Care Spec Pharm. 2024 Sep; 30(9):991-1000.